Woodstock Corp Acquires 14,113 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Woodstock Corp boosted its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 7.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 194,919 shares of the biotechnology company’s stock after purchasing an additional 14,113 shares during the quarter. Woodstock Corp owned about 0.33% of Aldeyra Therapeutics worth $973,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. State Street Corp raised its position in shares of Aldeyra Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after buying an additional 16,188 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Aldeyra Therapeutics by 163.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after acquiring an additional 295,864 shares during the last quarter. Federated Hermes Inc. purchased a new stake in Aldeyra Therapeutics during the second quarter valued at approximately $1,758,000. Barclays PLC lifted its stake in shares of Aldeyra Therapeutics by 280.1% in the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 48,313 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 397.0% in the 3rd quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock worth $15,480,000 after purchasing an additional 229,487 shares during the period. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Performance

NASDAQ ALDX opened at $4.78 on Friday. The business’s 50 day moving average price is $4.95 and its 200-day moving average price is $4.95. Aldeyra Therapeutics, Inc has a fifty-two week low of $2.71 and a fifty-two week high of $6.55. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.25). On average, analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.